Boston Millennia Partners
Boston Millennia Partners (BMP) is a Boston-based venture and growth equity firm focused on healthcare companies. For over 30 years BMP has invested in early and growth-stage healthcare IT, technology-enabled services, biopharma and medical device companies, using an active, hands-on ‘Core Company’ buy-and-build strategy to accelerate scale and strategic exits.
Boston Millennia Partners
Boston, Massachusetts, United States, North America
Services
Equity financing (venture and growth)
Provides first-round and follow-on equity investments across early and growth stages; typical initial investments range $250,000–$3,000,000 (some initial investments as small as $100,000), with follow-on financings that often double the original commitment.
Core Company (buy-and-build) M&A strategy
Leads and supports strategic acquisition programs to build scale around a platform company; BMP’s Core Companies have completed over 200 acquisitions.
Strategic guidance and market analysis
Hands-on support for corporate strategy, business development and market research to guide product positioning and growth plans.
Organizational development and executive recruiting
Identifies, sources and helps recruit senior management and board candidates; maintains a proprietary database of qualified executives.
Capital raising and syndicate organization
Leads capital raises and organizes investor syndicates; supports portfolio companies in accessing public and private capital.
Regulatory and clinical trial support
Assists portfolio companies with clinical trial design, FDA interactions and regulatory strategy (cited support in medical device and life-science investments).
Equity financing (venture and growth)
Provides first-round and follow-on equity investments across early and growth stages; typical initial investments range $250,000–$3,000,000 (some initial investments as small as $100,000), with follow-on financings that often double the original commitment.
Core Company (buy-and-build) M&A strategy
Leads and supports strategic acquisition programs to build scale around a platform company; BMP’s Core Companies have completed over 200 acquisitions.
Strategic guidance and market analysis
Hands-on support for corporate strategy, business development and market research to guide product positioning and growth plans.
Organizational development and executive recruiting
Identifies, sources and helps recruit senior management and board candidates; maintains a proprietary database of qualified executives.
Capital raising and syndicate organization
Leads capital raises and organizes investor syndicates; supports portfolio companies in accessing public and private capital.
Regulatory and clinical trial support
Assists portfolio companies with clinical trial design, FDA interactions and regulatory strategy (cited support in medical device and life-science investments).
Portfolio
Developed a wireless pulmonary artery sensor; acquired by St. Jude Medical for $450,000,000 (05/28/2014). BMP provided clinical trial design, capital raising and FDA navigation support.
#Medical device (remote monitoring for heart failure)
BMP was an early institutional investor and co-founder partner; Collegium completed IPO (05/07/2015, $70,000,000) and developed Xtampza ER with FDA approval processes.
#Specialty pharmaceuticals / drug reformulation
BMP invested in GlycoFi's first institutional round (2002), served on the board, helped recruit a CEO, raised $30M in additional financing; GlycoFi was acquired by Merck for $400,000,000 (2006) yielding ~10x return for BMP investors.
#Biotechnology / protein expression and glycosylation
Supported company growth, helped complete two Core acquisitions, assisted with IPO (Feb 1997) and product launch (Campath); acquired by Genzyme for $1 billion (2004).
#Biopharma / oncology
Develops minimally invasive joint resurfacing implant systems; markets in U.S. and multiple international markets.
#Orthopedic devices
Series G financing $40,000,000 (08/26/2014).
#Logistics and supply-chain technology
Developed a wireless pulmonary artery sensor; acquired by St. Jude Medical for $450,000,000 (05/28/2014). BMP provided clinical trial design, capital raising and FDA navigation support.
#Medical device (remote monitoring for heart failure)
BMP was an early institutional investor and co-founder partner; Collegium completed IPO (05/07/2015, $70,000,000) and developed Xtampza ER with FDA approval processes.
#Specialty pharmaceuticals / drug reformulation
BMP invested in GlycoFi's first institutional round (2002), served on the board, helped recruit a CEO, raised $30M in additional financing; GlycoFi was acquired by Merck for $400,000,000 (2006) yielding ~10x return for BMP investors.
#Biotechnology / protein expression and glycosylation
Supported company growth, helped complete two Core acquisitions, assisted with IPO (Feb 1997) and product launch (Campath); acquired by Genzyme for $1 billion (2004).
#Biopharma / oncology
Develops minimally invasive joint resurfacing implant systems; markets in U.S. and multiple international markets.
#Orthopedic devices
Series G financing $40,000,000 (08/26/2014).
#Logistics and supply-chain technology